Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors

No AccessJournal of Urology1 Aug 1976Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors A. Morales, D. Eidinger, and A.W. Bruce A. MoralesA. Morales Current address: Laboratory of Immunodiagnosis, Building 8, Room 118, National Institutes of Health, Bethesda, Maryland, 20014. More articles by this author , D. EidingerD. Eidinger More articles by this author , and A.W. BruceA.W. Bruce More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)58737-6AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin. The pattern of recurrence in 9 patients has been altered favorably. Although the findings are still preliminary they appear to hold promise of a new therapeutic approach to the treatment of a group of neoplasms for which effective therapy is still lacking. © 1976 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byDonin N, Lenis A, Holden S, Drakaki A, Pantuck A, Belldegrun A and Chamie K (2018) Immunotherapy for the Treatment of Urothelial CarcinomaJournal of Urology, VOL. 197, NO. 1, (14-22), Online publication date: 1-Jan-2017.Droller M (2016) Intracavitary bacillus Calmette-Guérin for Superficial Bladder TumorsJournal of Urology, VOL. 197, NO. 2S, (S146-S147), Online publication date: 1-Feb-2017.Yokomizo A, Kanimoto Y, Okamura T, Ozono S, Koga H, Iwamura M, Tanaka H, Takahashi S, Tsushima T, Kanayama H, Akaza H, Shinohara N, Mugiya S, Nomata K, Nakamura T and Naito S (2018) Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 195, NO. 1, (41-46), Online publication date: 1-Jan-2016.Gan C, Amery S, Chatterton K, Khan M, Thomas K and O’Brien T (2018) Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year OutcomesJournal of Urology, VOL. 195, NO. 6, (1697-1703), Online publication date: 1-Jun-2016.Holmäng S (2018) Patients with High Grade Bladder Cancer, and Tumor-Free 3 and 6-Month Cystoscopy after bacillus Calmette-Guérin have a Good Prognosis without Further Maintenance bacillus Calmette-GuérinUrology Practice, VOL. 3, NO. 1, (50-54), Online publication date: 1-Jan-2016.Barlow L, McKiernan J and Benson M (2018) Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin TherapyJournal of Urology, VOL. 189, NO. 3, (834-839), Online publication date: 1-Mar-2013.Johnson M, Nepple K, Peck V, Trinkaus K, Klim A, Sandhu G and Kibel A (2018) Randomized Controlled Trial of Oxybutynin Extended Release Versus Placebo for Urinary Symptoms During Intravesical Bacillus Calmette-Guérin TreatmentJournal of Urology, VOL. 189, NO. 4, (1268-1274), Online publication date: 1-Apr-2013.Brausi M, Witjes J, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H and Böhle A (2018) A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer GroupJournal of Urology, VOL. 186, NO. 6, (2158-2167), Online publication date: 1-Dec-2011.Alvarez-Múgica M, Cebrian V, Fernández-Gómez J, Fresno F, Escaf S and Sánchez-Carbayo M (2018) Myopodin Methylation is Associated With Clinical Outcome in Patients With T1G3 Bladder CancerJournal of Urology, VOL. 184, NO. 4, (1507-1513), Online publication date: 1-Oct-2010.DeCastro G and Steinberg G (2018) Are We Making Significant Progress in the Diagnosis and Management of Bladder Cancer?Journal of Urology, VOL. 183, NO. 5, (1667-1668), Online publication date: 1-May-2010.Nepple K, Lightfoot A, Rosevear H, O'Donnell M and Lamm D (2018) Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 184, NO. 5, (1915-1919), Online publication date: 1-Nov-2010.Rosevear H, Lightfoot A, Nepple K and O'Donnell M (2018) Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Plus Interferon α-2b Therapy for Nonmuscle Invasive Bladder Cancer in Patients With Prosthetic DevicesJournal of Urology, VOL. 184, NO. 5, (1920-1924), Online publication date: 1-Nov-2010.Bisiaux A, Thiounn N, Timsit M, Eladaoui A, Chang H, Mapes J, Mogenet A, Bresson J, Prié D, Béchet S, Baron C, Sadorge C, Thomas S, Albert E, Albert P and Albert M (2018) Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder CancerJournal of Urology, VOL. 181, NO. 4, (1571-1580), Online publication date: 1-Apr-2009.Huang G, Hamilton A, Lo M, Stein J and Penson D (2018) Predictors of Intravesical Therapy for Nonmuscle Invasive Bladder Cancer: Results From the Surveillance, Epidemiology and End Results Program 2003 Patterns of Care ProjectJournal of Urology, VOL. 180, NO. 2, (520-524), Online publication date: 1-Aug-2008.Herr H and Morales A (2018) History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success StoryJournal of Urology, VOL. 179, NO. 1, (53-56), Online publication date: 1-Jan-2008.Berglund R, Savage C, Vora K, Kurta J and Cronin A (2018) An Analysis of the Effect of Statin Use on the Efficacy of Bacillus Calmette-Guerin Treatment for Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 180, NO. 4, (1297-1300), Online publication date: 1-Oct-2008.Yu D, Lee C and Chang S (2018) Immunotherapy for Orthotopic Murine Bladder Cancer Using Bacillus Calmette-Guerin Recombinant Protein Mpt-64Journal of Urology, VOL. 177, NO. 2, (738-742), Online publication date: 1-Feb-2007.Smith E, Schwartz M, Kawamoto H, You X, Hwang D, Liu H and Scherr D (2018) Antitumor Effects of Imidazoquinolines in Urothelial Cell Carcinoma of the BladderJournal of Urology, VOL. 177, NO. 6, (2347-2351), Online publication date: 1-Jun-2007.Griffith T (2018) Predicting Bacillus Calmette-Guerin Immunotherapy EffectivenessJournal of Urology, VOL. 178, NO. 6, (2247-2248), Online publication date: 1-Dec-2007.Koya M, Simon M and Soloway M (2018) Complications of Intravesical Therapy for Urothelial Cancer of the BladderJournal of Urology, VOL. 175, NO. 6, (2004-2010), Online publication date: 1-Jun-2006.LEE C, CHANG S, HSIEH D and YU D (2018) Immunotherapy for Bladder Cancer Using Recombinant Bacillus Calmette-Guerin DNA Vaccines and Interleukin-12 DNA VaccineJournal of Urology, VOL. 171, NO. 3, (1343-1347), Online publication date: 1-Mar-2004.VOLKMER B, GSCHWEND J, MAIER S, SEIDL-SCHLICK E, BACH D and ROMICS I (2018) T2a Transitional Cell Carcinoma of the Bladder: Long-term Experience With Intravesical Immunoprophylaxis With Bacillus Calmette-guerinJournal of Urology, VOL. 169, NO. 3, (931-935), Online publication date: 1-Mar-2003.BİLEN C, İNCİ K, ERKAN İ and ÖZEN H (2018) The Predictive Value Of Purified Protein Derivative Results On Complications And Prognosis In Patients With Bladder Cancer Treated With Bacillus Calmette-GuerinJournal of Urology, VOL. 169, NO. 5, (1702-1705), Online publication date: 1-May-2003.PEYROMAURE M, GUERIN F, AMSELLEM-OUAZANA D, SAIGHI D, DEBRE B and ZERBIB M (2018) Intravesical Bacillus Calmette-Guerin Therapy for Stage T1 Grade 3 Transitional Cell Carcinoma of the Bladder: Recurrence, Progression and Survival in a Study of 57 PatientsJournal of Urology, VOL. 169, NO. 6, (2110-2112), Online publication date: 1-Jun-2003.BÖHLE A and BRANDAU S (2018) Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder CancerJournal of Urology, VOL. 170, NO. 3, (964-969), Online publication date: 1-Sep-2003.SAINT F, PATARD J, MAILLE P, SOYEUX P, HOZNEK A, SALOMON L, ABBOU C and CHOPIN D (2018) PROGNOSTIC VALUE OF A T HELPER 1 URINARY CYTOKINE RESPONSE AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN TREATMENT FOR SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 167, NO. 1, (364-367), Online publication date: 1-Jan-2002.THIOUNN N, PAGES F, MEJEAN A, DESCOTES J, FRIDMAN W and ROMET-LEMONNE J (2018) Adoptive Immunotherapy For Superficial Bladder Cancer With Autologous Macrophage Activated Killer CellsJournal of Urology, VOL. 168, NO. 6, (2373-2376), Online publication date: 1-Dec-2002.Chen F, Crist S, Zhang G, Iwamoto Y and See W (2018) Interleukin-6 Production by Human Bladder Tumor Cell Lines is Up-Regulated by Bacillus Calmette-Guerin Through Nuclear Factor-κB and Ap-1 Via an Immediate Early PathwayJournal of Urology, VOL. 168, NO. 2, (786-797), Online publication date: 1-Aug-2002.GRIFFITHS T, CHARLTON M, NEAL D and POWELL P (2018) Treatment of Carcinoma In Situ With Intravesical Bacillus Calmette-Guerin Without MaintenanceJournal of Urology, VOL. 167, NO. 6, (2408-2412), Online publication date: 1-Jun-2002.SAINT F, PATARD J, MAILLE P, SOYEUX P, HOZNEK A, SALOMON L, DE LA TAILLE A, ABBOU C and CHOPIN D (2018) T HELPER 1/2 LYMPHOCYTE URINARY CYTOKINE PROFILES IN RESPONDING AND NONRESPONDING PATIENTS AFTER 1 AND 2 COURSES OF BACILLUS CALMETTE-GUERIN FOR SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 166, NO. 6, (2142-2147), Online publication date: 1-Dec-2001.MACK D, HÖLTL W, BASSI P, BRAUSI M, FERRARI P, de BALINCOURT C and SYLVESTER R (2018) THE ABLATIVE EFFECT OF QUARTER DOSE BACILLUS CALMETTE-GUERIN ON A PAPILLARY MARKER LESION OF THE BLADDERJournal of Urology, VOL. 165, NO. 2, (401-403), Online publication date: 1-Feb-2001.TAKAHASHI T, KUSHIRO A, NOMOTO K, UCHIDA K, MOROTOMI M, YOKOKURA T and AKAZA H (2018) ANTITUMOR EFFECTS OF THE INTRAVESICAL INSTILLATION OF HEAT KILLED CELLS OF THE LACTOBACILLUS CASEI STRAIN SHIROTA ON THE MURINE ORTHOTOPIC BLADDER TUMOR MBT-2Journal of Urology, VOL. 166, NO. 6, (2506-2511), Online publication date: 1-Dec-2001.MORALES A, CHIN J and RAMSEY E (2018) MYCOBACTERIAL CELL WALL EXTRACT FOR TREATMENT OF CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 166, NO. 5, (1633-1638), Online publication date: 1-Nov-2001.PALOU J, LAGUNA P, MILLÁN-RODRÍGUEZ F, HALL R, SALVADOR-BAYARRI J and VICENTE-RODRÍGUEZ J (2018) CONTROL GROUP AND MAINTENANCE TREATMENT WITH BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU AND/OR HIGH GRADE BLADDER TUMORSJournal of Urology, VOL. 165, NO. 5, (1488-1491), Online publication date: 1-May-2001.DUREK C, RICHTER E, BASTECK A, RÜSCH-GERDES S, GERDES J, JOCHAM D and BÖHLE A (2018) THE FATE OF BACILLUS CALMETTE-GUERIN AFTER INTRAVESICAL INSTILLATIONJournal of Urology, VOL. 165, NO. 5, (1765-1768), Online publication date: 1-May-2001.KIM J and STEINBERG G (2018) THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 165, NO. 3, (745-756), Online publication date: 1-Mar-2001.PEEKER R, HAGHSHENO M, HOLMÄNG S and FALL M (2018) INTRAVESICAL BACILLUS CALMETTE-GUERIN AND DIMETHYL SULFOXIDE FOR TREATMENT OF CLASSIC AND NONULCER INTERSTITIAL CYSTITIS:: A PROSPECTIVE, RANDOMIZED DOUBLE-BLIND STUDYJournal of Urology, VOL. 164, NO. 6, (1912-1916), Online publication date: 1-Dec-2000.THALMANN G, SERMIER A, RENTSCH C, MÖHRLE K, CECCHINI M and STUDER U (2018) URINARY INTERLEUKIN-8 AND 18 PREDICT THE RESPONSE OF SUPERFICIAL BLADDER CANCER TO INTRAVESICAL THERAPY WITH BACILLUS CALMETTE-GUERINJournal of Urology, VOL. 164, NO. 6, (2129-2133), Online publication date: 1-Dec-2000.AYGÜN C, ÖZEN H, KOCAGÖZ T, SARIBAŞ Z, AKI T and TEKIN i (2018) INDUCTION OF MYCOBACTEREMIA BY INTRAVESICAL BACILLUS CALMETTE-GUERIN INSTILLATION IN AN EXPERIMENTAL ANIMAL MODEL AND DETECTION WITH POLYMERASE CHAIN REACTIONJournal of Urology, VOL. 163, NO. 5, (1588-1590), Online publication date: 1-May-2000.LAMM D, BLUMENSTEIN B, CRISSMAN J, MONTIE J, GOTTESMAN J, LOWE B, SAROSDY M, BOHL R, GROSSMAN H, BECK T, LEIMERT J and CRAWFORD E (2018) MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, VOL. 163, NO. 4, (1124-1129), Online publication date: 1-Apr-2000.LEBRET T, BOHIN D, KASSARDJIAN Z, HERVE J, MOLINIE V, BARRE P, LUGAGNE P and BOTTO H (2018) RECURRENCE, PROGRESSION AND SUCCESS IN STAGE TA GRADE 3 BLADDER TUMORS TREATED WITH LOW DOSE BACILLUS CALMETTE-GUERIN INSTILLATIONSJournal of Urology, VOL. 163, NO. 1, (63-67), Online publication date: 1-Jan-2000.LOSA A, HURLE R and LEMBO A (2018) LOW DOSE BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER: LONG-TERM RESULTSJournal of Urology, VOL. 163, NO. 1, (68-72), Online publication date: 1-Jan-2000.ELSÄSSER-BEILE U, GUTZEIT O, BAUER S, KATZENWADEL A, SCHULTZE-SEEMANN W and WETTERAUER U (2018) SYSTEMIC AND LOCAL IMMUNOMODULATORY EFFECTS OF INTRAVESICAL BCG THERAPY IN PATIENTS WITH SUPERFICIAL URINARY BLADDER CARCINOMASJournal of Urology, VOL. 163, NO. 1, (296-299), Online publication date: 1-Jan-2000.ZHANG Y, KHOO H and ESUVARANATHAN K (2018) EFFECTS OF BACILLUS CALMETTE-GUERIN AND INTERFERON alpha-2B ON CYTOKINE PRODUCTION IN HUMAN BLADDER CANCER CELL LINESJournal of Urology, VOL. 161, NO. 3, (977-983), Online publication date: 1-Mar-1999.ALI-EL-DEIN B, NABEEH A, ISMAIL E and GHONEIM M (2018) SEQUENTIAL BACILLUS CALMETTE-GUERIN AND EPIRUBICIN VERSUS BACILLUS CALMETTE-GUERIN ALONE FOR SUPERFICIAL BLADDER TUMORS: A RANDOMIZED PROSPECTIVE STUDYJournal of Urology, VOL. 162, NO. 2, (339-342), Online publication date: 1-Aug-1999.ZLOTTA A, DROWART A, VAN VOOREN J, SHEKARSARAI H, DE COCK M, PIRSON M, PALFLIET K, JURION F, SIMON J, SCHULMAN C and HUYGEN K (2018) SUPERFICIAL BLADDER TUMORS AND INCREASED REACTIVITY AGAINST MYCOBACTERIAL ANTIGENS BEFORE BACILLUS CALMETTE-GUERIN THERAPYJournal of Urology, VOL. 159, NO. 6, (1885-1891), Online publication date: 1-Jun-1998.NEMOTO R, NAKAMURA I, HONJYO I, TAKAHASHI M and ABE C (2018) TUBERCULOUS ENTERITIS AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY: A CASE OF MISTAKEN IDENTITYJournal of Urology, VOL. 159, NO. 6, (2091-2092), Online publication date: 1-Jun-1998.RAMONER R, RIESER C, HEROLD M, KLOCKER H, BARTSCH G, STENZL A and THURNHER M (2018) ACTIVATION OF HUMAN DENDRITIC CELLS BY BACILLUS CALMETTE-GUERINJournal of Urology, VOL. 159, NO. 5, (1488-1492), Online publication date: 1-May-1998.Cookson M, Herr H, Zhang Z, Soloway S, Sogani P and Fair W (2018) The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year OutcomeJournal of Urology, VOL. 158, NO. 1, (62-67), Online publication date: 1-Jul-1997.Thalmann G, Dewald B, Baggiolini M and Studer U (2018) INTERLEUKIN-8 EXPRESSION IN THE URINE AFTER BACILLUS CALMETTE-GUERIN THERAPY: A POTENTIAL PROGNOSTIC FACTOR OF TUMOR RECURRENCE AND PROGRESSIONJournal of Urology, VOL. 158, NO. 4, (1340-1344), Online publication date: 1-Oct-1997.Downs T, Szilvasi A and O'Donnell M (2018) PHARMACOLOGICAL BIOCOMPATIBILITY BETWEEN INTRAVESICAL PREPARATIONS OF BCG AND INTERFERON-ALPHA 2BJournal of Urology, VOL. 158, NO. 6, (2311-2315), Online publication date: 1-Dec-1997.Vegt P, van der Meijden A, Sylvester R, Brausi M, Holtl W and de Balincourt C (2018) Does Isoniazid Reduce Side Effects of Intravesical Bacillus Calmette-Guerin Therapy in Superficial Bladder Cancer? Interim Results of European Organization for Research and Treatment of Cancer Protocol 30911Journal of Urology, VOL. 157, NO. 4, (1246-1249), Online publication date: 1-Apr-1997.Ali-El Dein B and Nabeeh A (2018) Tuberculous Iliac Lymphadenitis: A Rare Complication of Intravesical Bacillus Calmette-Guerin and Cause of Tumor Over StagingJournal of Urology, VOL. 156, NO. 5, (1766-1767), Online publication date: 1-Nov-1996.Hurle R, Losa A, Ranieri A, Graziotti P and Lembo A (2018) Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer TherapyJournal of Urology, VOL. 156, NO. 5, (1602-1605), Online publication date: 1-Nov-1996.Okamura T, Tozawa K, Yamada Y, Sakagami H, Ueda K and Kohri K (2018) Clinicopathological Evaluation of Repeated Courses of Intravesical Bacillus Calmette-Guerin Instillation for Preventing Recurrence of Initially Resistant Superficial Bladder CancerJournal of Urology, VOL. 156, NO. 3, (967-971), Online publication date: 1-Sep-1996.Sander B, Damm O, Gustafsson B, Andersson U and Hakansson L (2018) Localization of IL-1, IL-2, IL-4, IL-8 and TNF in Superficial Bladder Tumors Treated with Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 156, NO. 2, (536-541), Online publication date: 1-Aug-1996.de Reijke T, de Boer E, Kurth K and Schamhart D (2018) Urinary Cytokines During Intravesical Bacillus Calmetteguerin Therapy for Superficial Bladder Cancer: Processing, Stability and Prognostic ValueJournal of Urology, VOL. 155, NO. 2, (477-482), Online publication date: 1-Feb-1996.Glazier D, Bahnson R, McLeod D, von Roemeling R, Messing E and Ernstoff M (2018) Intravesical Recombinant Tumor Necrosis Factor in the Treatment of Superficial Bladder Cancer: An Eastern Cooperative Oncology Group StudyJournal of Urology, VOL. 154, NO. 1, (66-68), Online publication date: 1-Jul-1995.Wishahi M, Ismail I, Ruebben H and Otto T (2018) Original Articles: Bladder Cancer: Keyhole-Limpet Hemocyanin Immunotherapy in the Bilharzial Bladder: A New Treatment Modality? Phase II Trial: Superficial Bladder CancerJournal of Urology, VOL. 153, NO. 3S, (926-928), Online publication date: 1-Mar-1995.Kamat M, Kulkarni J, Tongaonkar H and Dalal A (2018) Intravesical Bacillus Calmette-Guerin For Superficial Bladder Cancer: Experience With Danish 1331 StrainJournal of Urology, VOL. 152, NO. 5 Part 1, (1424-1428), Online publication date: 1-Nov-1994.Cheng D, Shu W, Choi J, Margolis E, Droller M and Liu B (2018) Bacillus Calmette-Guérin Interacts with the Carboxyl-Terminal Heparin Binding Domain of Fibronectin: Implications for BCG-Mediated Antitumor ActivityJournal of Urology, VOL. 152, NO. 4, (1275-1280), Online publication date: 1-Oct-1994.Nadler R, Catalona W, Hudson M and Ratliff T (2018) Durability of the Tumor-Free Response for Intravesical Bacillus Calmette-Guerin TherapyJournal of Urology, VOL. 152, NO. 2 Part 1, (367-373), Online publication date: 1-Aug-1994.Soloway M (2018) Editorial: Intravesical Therapy for Bladder CancerJournal of Urology, VOL. 152, NO. 2 Part 1, (379-381), Online publication date: 1-Aug-1994.Mizutani Y, Nio Y, Fukumoto M and Yoshida O (2018) Enhanced Antitumor Effect of Bacillus Calmette-Guérin in Combination with Fibrinogen on Urinary Bladder TumorJournal of Urology, VOL. 151, NO. 5, (1420-1426), Online publication date: 1-May-1994.Ratliff T, Ritchey J, Yuan J, Andriole G and Catalona W (2018) T-Cell Subsets Required for Intravesical BCG Immunotherapy for Bladder CancerJournal of Urology, VOL. 150, NO. 3, (1018-1023), Online publication date: 1-Sep-1993.Izes J, Bihrle W and Thomas C (2018) Corticosteroid-Associated Fatal Mycobacterial Sepsis Occurring 3 Years after Instillation of Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 150, NO. 5 Part 1, (1498-1500), Online publication date: 1-Nov-1993.Sharpe J, Duffy G and Chin J (2018) Intrarenal Bacillus Calmette-Guerin Therapy for Upper Urinary Tract Carcinoma in SituJournal of Urology, VOL. 149, NO. 3, (457-459), Online publication date: 1-Mar-1993.Soloway M (2018) Editorial CommentJournal of Urology, VOL. 149, NO. 3, (459-460), Online publication date: 1-Mar-1993.Fishman J, Walton D, Flynn N, Benson D and Devere White R (2018) Tuberculous Spondylitis as A Complication of Intravesical Bacillus Calmette-Guerin TherapyJournal of Urology, VOL. 149, NO. 3, (584-587), Online publication date: 1-Mar-1993.Melekos M, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G and Dauaher H (2018) Intravesical Bacillus Calmette-Guerin Immunoprophylaxis of Superficial Bladder Cancer: Results of a Controlled Prospective Trial with Modified Treatment ScheduleJournal of Urology, VOL. 149, NO. 4, (744-748), Online publication date: 1-Apr-1993.Cookson M and Sarosdy M (2018) Management of Stage T1 Superficial Bladder Cancer with Intravesical Bacillus Calmette-Guerin TherapyJournal of Urology, VOL. 148, NO. 3 Part 1, (797-801), Online publication date: 1-Sep-1992.Gonzalez J, Marcol B and Wolf M (2018) Complications of Intravesical Bacillus Calmette-Guerin: A Case ReportJournal of Urology, VOL. 148, NO. 6, (1892-1893), Online publication date: 1-Dec-1992.Böhle A, Kirsten D, Schröder K, Knipper A, Fornara P, Magnussen H and Jocham D (2018) Clinical Evidence of Systemic Persistence of Bacillus Calmette-Guerin: Long-Term Pulmonary Bacillus Calmette-Guerin Infection After Intravesical Therapy for Bladder Cancer and Subsequent CystectomyJournal of Urology, VOL. 148, NO. 6, (1894-1897), Online publication date: 1-Dec-1992.Eure G, Cundiff M and Schellhammer P (2018) Bacillus Calmette-Guerin Therapy for High Risk Stage T1 Superficial Bladder CancerJournal of Urology, VOL. 147, NO. 2, (376-379), Online publication date: 1-Feb-1992.Molina J, Rabian C, D’agay M and Modai J (2018) Hypersen sitivity Systemic Reaction Following Intravesical Bacillus Calmette-Guerin: Successful Treatment With SteroidsJournal of Urology, VOL. 147, NO. 3 Part 1, (695-697), Online publication date: 1-Mar-1992.Morales A, Nickel J and Wilson J (2018) Dose-Response of Bacillus Calmette-Guerin in the Treatment of Superficial Bladder CancerJournal of Urology, VOL. 147, NO. 5, (1256-1258), Online publication date: 1-May-1992.Herr H (2018) Editorial CommentsJournal of Urology, VOL. 147, NO. 5, (1258-1258), Online publication date: 1-May-1992.Hawkyard S, Jackson A, James K, Prescott S, Smyth J and Chisholm G (2018) The Inhibitory Effects of Interferon Gamma on the Growth of Bladder Cancer CellsJournal of Urology, VOL. 147, NO. 5, (1399-1403), Online publication date: 1-May-1992.Lamm D (2018) Editorial CommentsJournal of Urology, VOL. 147, NO. 5, (1258-1258), Online publication date: 1-May-1992.Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D and Garbeglio A (2018) A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?Journal of Urology, VOL. 146, NO. 1, (32-35), Online publication date: 1-Jul-1991.Naito K, Hisazumi H, Uchibayashi T, Amano T, Hirata A, Komatsu K, Ishida T and Miyoshi N (2018) Integral Laser Photodynamic Treatment of Refractory Multifocal Bladder TumorsJournal of Urology, VOL. 146, NO. 6, (1541-1545), Online publication date: 1-Dec-1991.Rubenstein M, Muchnik S, Chet M, Shaw M, McKiel C and Guinan P (2018) Tumor Infiltrating Lymphocytes: The Effect of Bacillus Calmette Guerin on Helper/Suppressor-T Cell Ratios of Treated and Untreated TumorsJournal of Urology, VOL. 146, NO. 6, (1650-1653), Online publication date: 1-Dec-1991.Levi D’Ancona C, Rodrigues Netto N, Almeida Claro J and Ikari O (2018) Oral or Intravesical Bacillus Calmette-Guerin Immunoprophylaxis in Bladder CarcinomaJournal of Urology, VOL. 145, NO. 3, (498-501), Online publication date: 1-Mar-1991.See W, McDermott T, Xia Q and Williams R (2018) A Continuous Intravesical Drug Delivery System for the RatJournal of Urology, VOL. 145, NO. 3, (596-599), Online publication date: 1-Mar-1991.Lamm D, DeHaven J, Shriver J and Sarosdy M (2018) Prospective Randomized Comparison of Intravesical with Percutaneous Bacillus Calmette-Guerin Versus Intravesical Bacillus Calmette-Guerin in Superficial Bladder CancerJournal of Urology, VOL. 145, NO. 4, (738-740), Online publication date: 1-Apr-1991. (2018) Reply by AuthorsJournal of Urology, VOL. 146, NO. 3, (769-770), Online publication date: 1-Sep-1991.Böhle A, Gerdes J, Ulmer A, Hofstetter A and Flad H (2018) Effects of Local Bacillus Calmette-Guerin Therapy in Patients with Bladder Carcinoma on Immunocompetent Cells of the Bladder WallJournal of Urology, VOL. 144, NO. 1, (53-58), Online publication date: 1-Jul-1990.Böhle A, Nowc C, Ulmer A, Musehold J, Gerdes J, Hofstetter A and Flad H (2018) Elevations of Cytokines Interleukin-1, Interleukin-2 and Tumor Necrosis Factor in the Urine of Patients after Intravesical Bacillus Calmette-Guerin ImmunotherapyJournal of Urology, VOL. 144, NO. 1, (59-64), Online publication date: 1-Jul-1990.Coplen D, Marcus M, Myers J, Ratliff T and Catalona W (2018) Long-Term Followup of Patients Treated With 1 or 2, 6-Week Courses of Intravesical Bacillus Calmette-Guerin: Analysis of Possible Predictors of Response Free of TumorJournal of Urology, VOL. 144, NO. 3, (652-657), Online publication date: 1-Sep-1990.Hudson M, Yuan J, Catalona W and Ratliff T (2018) Adverse Impact of Fibrin Clot Inhibitors on Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder TumorsJournal of Urology, VOL. 144, NO. 6, (1362-1364), Online publication date: 1-Dec-1990.Tsujihashi H, Matsuda H, Uejima S, Akiyama T and Kurita T (2018) The Kinetics of Cellular Proliferation in Rat Urinary Bladder Treated with N-Butyl-N-(4-Hydroxybutyl)NitrosamineJournal of Urology, VOL. 144, NO. 6, (1493-1496), Online publication date: 1-Dec-1990.Carballido J, Alvarez-Mon M, Solovera J, Menéndez-Ondina L and Durántez A (2018) Clinical Significance of Natural Killer Activity in Patients with Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 143, NO. 1, (29-33), Online publication date: 1-Jan-1990.Martínez Piñeiro J, León J, Martínez Piñeiro L, Fiter L, Mosteiro J, Navarro J, García Matres M and Cárcamo P (2018) Bacillus Calmette-Guerin Versus Doxorubicin Versus Thiotepa: A Randomized Prospective Study in 202 Patients with Superficial Bladder CancerJournal of Urology, VOL. 143, NO. 3, (502-506), Online publication date: 1-Mar-1990.Bretton P, Herr H, Kimmel M, Whitmore W, Laudone V, Oettgen H and Fair W (2018) The Response of Patients with Superficial Bladder Cancer to a Second Course of Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 143, NO. 4, (710-712), Online publication date: 1-Apr-1990.Ratliff T (2018) Editorial CommentsJournal of Urology, VOL. 143, NO. 4, (712-712), Online publication date: 1-Apr-1990.Sarosdy M and Lamm D (2018) Long-Term Results of Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder CancerJournal of Urology, VOL. 142, NO. 3, (719-722), Online publication date: 1-Sep-1989.Herr H (2018) Editorial CommentJournal of Urology, VOL. 142, NO. 3, (722-722), Online publication date: 1-Sep-1989.Hudson M, Catalona W, Ritchey J, Aslanzadeh J, Brown E and Ratliff T (2018) Choice of an Optimal Diluent for Intravesical Bacillus Calmette-Guerin AdministrationJournal of Urology, VOL. 142, NO. 6, (1438-1441), Online publication date: 1-Dec-1989.Bretton P, Herr H, Whitmore W, Badalament R, Kimmel M, Provet J, Oettgen H, Melamed M and Fair W (2018) Intravesical Bacillus Calmette-Guerin Therapy for in situ Transitional Cell Carcinoma Involving the Prostatic UrethraJournal of Urology, VOL. 141, NO. 4, (853-855), Online publication date: 1-Apr-1989.Lamm D (2018) Editorial CommentsJournal of Urology, VOL. 141, NO. 4, (855-855), Online publication date: 1-Apr-1989.Linn R, Klimberg I and Wajsman Z (2018) Persistent Acid-Fast Bacilli Following Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 141, NO. 5, (1197-1198), Online publication date: 1-May-1989.Tsujihashi H, Matsuda H, Uejima S, Akiyama T and Kurita T (2018) Immunoresponse of Tissue Infiltrating Lymphocytes in Bladder TumorsJournal of Urology, VOL. 141, NO. 6, (1467-1470), Online publication date: 1-Jun-1989.Soloway M (2018) Editorial CommentsJournal of Urology, VOL. 141, NO. 4, (855-856), Online publication date: 1-Apr-1989.Ibrahiem E, Ghoneim M, Nigam V, Brailovsky C and Elhilali M (2018) Prophylactic Maltose Tetrapalmitate and Bacillus Calmette-Guerin Immunotherapy of Recurrent Superficial Bladder Tumors: Preliminary ReportJournal of Urology, VOL. 140, NO. 3, (498-500), Online publication date: 1-Sep-1988.Woolley J, Lau B, Ruckle H and Torrey R (2018) Phagocytic and Natural Killer Cytotoxic Responses of Murine Transitional Cell Carcinoma to Postsurgical ImmunochemotherapyJournal of Urology, VOL. 140, NO. 3, (660-663), Online publication date: 1-Sep-1988.Oates R, Stilmant M, Freedlund M and Siroky M (2018) Granulomatous Prostatitis Following Bacillus Calmette-Guerin Immunotherapy of Bladder CancerJournal of Urology, VOL. 140, NO. 4, (751-754), Online publication date: 1-Oct-1988.Tsujihashi H, Matsuda H, Uejima S, Akiyama T and Kurita T (2018) Immunocompetence of Tissue Infiltrating Lymphocytes in Bladder TumorsJournal of Urology, VOL. 140, NO. 4, (890-894), Online publication date: 1-Oct-1988.Hillyard R, Ladaga L and Schellhammer P (2018) Superficial Transitional Cell Carcinoma of the Bladder Associated with Mucosal Involvement of the Prostatic Urethra: Results of Treatment with Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 139, NO. 2, (290-293), Online publication date: 1-Feb-1988.Herr H (2018) Editorial CommentJournal of Urology, VOL. 139, NO. 2, (293-293), Online publication date: 1-Feb-1988.Kavoussi L, Torrence R, Gillen D, Hudson M, Haaff E, Dresner S, Ratliff T and Catalona W (2018) Results of 6 Weekly Intravesical Bacillus Calmette-Guerin Instillations on the Treatment of Superficial Bladder TumorsJournal of Urology, VOL. 139, NO. 5, (935-940), Online publication date: 1-May-1988.Torrence R, Kavoussi L, Catalona W and Ratliff T (2018) Prognostic Factors in Patients Treated with Intravesical Bacillus Calmette-Guerin for Superficial Bladder CancerJournal of Urology, VOL. 139, NO. 5, (941-944), Online publication date: 1-May-1988.Herr H and Whitmore W (2018) Ureteral Carcinoma in Situ After Successful Intravesical Therapy for Superficial Bladder Tumors: Incidence, Possible Pathogenesis and ManagementJournal of Urology, VOL. 138, NO. 2, (292-294), Online publication date: 1-Aug-1987.Catalona W (2018) Editorial CommentJournal of Urology, VOL. 138, NO. 2, (294-294), Online publication date: 1-Aug-1987.Hudson M, Ratliff T, Gillen D, Haaff E, Dresner S and Catalona W (2018) Single Course Versus Maintenance Bacillus Calmette-Guerin Therapy for Superficial Bladder Tumors: A Prospective, Randomized TrialJournal of Urology, VOL. 138, NO. 2, (295-298), Online publication date: 1-Aug-1987.DeKernion J (2018) Editorial CommentsJournal of Urology, VOL. 138, NO. 2, (298-298), Online publication date: 1-Aug-1987.Pansadoro V and De Paula F (2018) Intravesical Bacillus Calmette-Guerin in the Treatment of Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 138, NO. 2, (299-301), Online publication date: 1-Aug-1987.Herr H, Laudone V and Whitmore W (2018) An Overview of Intravesical Therapy for Superficial Bladder TumorsJournal of Urology, VOL. 138, NO. 6, (1363-1368), Online publication date: 1-Dec-1987.Nakamura K, Chiao J, Nagamatsu G and Addonizio J (2018) Monocyte Cytolytic Factor in Promoting Monocyte-Mediated Lysis of Bladder Cancer Cells by Bacillus Calmette-GuerinJournal of Urology, VOL. 138, NO. 4 Part 1, (867-870), Online publication date: 1-Oct-1987.Jakse G, Loidl W, Seeber G and Hofstädter F (2018) Stage T1, Grade 3 Transitional Cell Carcinoma of the Bladder: An Unfavorable Tumor?Journal of Urology, VOL. 137, NO. 1, (39-43), Online publication date: 1-Jan-1987.Merguerian P, Donahue L and Cockett A (2018) Intraluminal Interleukin 2 and Bacillus Calmette-Guerin for Treatment of Bladder Cancer: A Preliminary ReportJournal of Urology, VOL. 137, NO. 2, (216-219), Online publication date: 1-Feb-1987.Marsh C, Torrey R, Woolley J, Barker G and Lau B (2018) Superiority of Intravesical Immunotherapy with Corynebacterium Parvum and Allium Sativum in Control of Murine Bladder CancerJournal of Urology, VOL. 137, NO. 2, (359-362), Online publication date: 1-Feb-1987.Huland H, Arndt R, Huland E, Loening T and Steffens M (2018) Monoclonal Antibody 486 P 3/12: A Valuable Bladder Carcinoma Marker for ImmunocytologyJournal of Urology, VOL. 137, NO. 4, (654-659), Online publication date: 1-Apr-1987.Soloway M and Perry A (2018) Bacillus Calmette-Guerin for Treatment of Superficial Transitional Cell Carcinoma of the Bladder in Patients who have failed Thiotepa and/or Mitomycin CJournal of Urology, VOL. 137, NO. 5, (871-873), Online publication date: 1-May-1987.Catalona W (2018) Editorial CommentJournal of Urology, VOL. 137, NO. 5, (873-873), Online publication date: 1-May-1987.Lee K, Weiss G, O’Donnell R and Cockett A (2018) Reduction of Bladder Cancer Growth in Mice Treated with Intravesical Bacillus Calmette Guerin and Systemic Interleukin 2Journal of Urology, VOL. 137, NO. 6, (1270-1273), Online publication date: 1-Jun-1987. (2018) Reply by AuthorsJournal of Urology, VOL. 138, NO. 2, (294-294), Online publication date: 1-Aug-1987.Lamm D (2018) Editorial CommentsJournal of Urology, VOL. 138, NO. 2, (298-298), Online publication date: 1-Aug-1987. (2018) Reply by AuthorsJournal of Urology, VOL. 138, NO. 2, (298-298), Online publication date: 1-Aug-1987.Lau B, Woolley J, Marsh C, Barker G, Koobs D and Torrey R (2018) Superiority of Intralesional Immunotherapy with Corynebacterium Parvum and Allium Sativum in Control of Murine Transitional Cell CarcinomaJournal of Urology, VOL. 136, NO. 3, (701-705), Online publication date: 1-Sep-1986.Haaff E, Dresner S, Ratliff T and Catalona W (2018) Two Courses of Intravesical Bacillus Calmette-Guerin for Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 136, NO. 4, (820-823), Online publication date: 1-Oct-1986.Lamm D (2018) Editorial CommentJournal of Urology, VOL. 136, NO. 4, (823-824), Online publication date: 1-Oct-1986.Haaff E, Catalona W and Ratliff T (2018) Detection of Interleukin 2 in the Urine of Patients with Superficial Bladder Tumors after Treatment with Intravesical BCGJournal of Urology, VOL. 136, NO. 4, (970-974), Online publication date: 1-Oct-1986.Klimberg I and Wajsman Z (2018) Treatment for Muscle Invasive Carcinoma of the BladderJournal of Urology, VOL. 136, NO. 6, (1169-1175), Online publication date: 1-Dec-1986.Morales A and Pang A (2018) Prophylaxis and Therapy of an Experimental Bladder Cancer with Biological Response ModifiersJournal of Urology, VOL. 135, NO. 1, (191-193), Online publication date: 1-Jan-1986.Schellhammer P, Ladaga L and Fillion M (2018) Bacillus Calmette-Guerin for Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 135, NO. 2, (261-264), Online publication date: 1-Feb-1986.Kelley D, Haaff E, Becich M, Lage J, Bauer W, Dresner S, Catalona W and Ratliff T (2018) Prognostic Value of Purified Protein Derivative Skin Test and Granuloma Formation in Patients Treated with Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 135, NO. 2, (268-271), Online publication date: 1-Feb-1986.Droller M (2018) Bacillus Calmette-Guerin in the Management of Bladder CancerJournal of Urology, VOL. 135, NO. 2, (331-333), Online publication date: 1-Feb-1986.Stanisic T, Brewer M and Graham A (2018) Intravesical Bacillus Calmette-Guerin Therapy and Associated Granulomatous Renal MassesJournal of Urology, VOL. 135, NO. 2, (356-358), Online publication date: 1-Feb-1986.Lage J, Bauer W, Kelley D, Ratliff T and Catalona W (2018) Histological Parameters and Pitfalls in the Interpretation of Bladder Biopsies in Bacillus Calmette-Guerin Treatment of Superficial Bladder CancerJournal of Urology, VOL. 135, NO. 5, (916-919), Online publication date: 1-May-1986.Brosman S (2018) The Use of Bacillus Calmette-Guerin in the Therapy of Bladder Carcinoma in SituJournal of Urology, VOL. 134, NO. 1, (36-39), Online publication date: 1-Jul-1985.Lamm D (2018) Bacillus Calmette-Guerin Immunotherapy for Bladder CancerJournal of Urology, VOL. 134, NO. 1, (40-46), Online publication date: 1-Jul-1985.Catalona W (2018) Editorial CommentsJournal of Urology, VOL. 134, NO. 1, (46-47), Online publication date: 1-Jul-1985.Kelley D, Ratliff T, Catalona W, Shapiro A, Lage J, Bauer W, Haaff E and Dresner S (2018) Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer: Effect of Bacillus Calmette-Guerin Viability on Treatment ResultsJournal of Urology, VOL. 134, NO. 1, (48-53), Online publication date: 1-Jul-1985.Huland H, Otto U and Paleske A (2018) Chemotherapy and Human Bladder Carcinoma Transplanted into NMRI NU/NU MiceJournal of Urology, VOL. 134, NO. 3, (601-606), Online publication date: 1-Sep-1985.Droller M (2018) Immunotherapy in Genitourinary NeoplasiaJournal of Urology, VOL. 133, NO. 1, (1-5), Online publication date: 1-Jan-1985.deKernion J, Huang M, Lindner A, Smith R and Kaufman J (2018) The Management of Superficial Bladder Tumors and Carcinoma in situ with Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 133, NO. 4, (598-600), Online publication date: 1-Apr-1985.Staiano-coico L, Huffman J, Wolf R, Pinsky C, Herr H, Whitmore F, Oettgen H, Darzynkiewicz Z and Melamed M (2018) Monitoring Intravesical Bacillus Calmette-guerin Treatment of Bladder Carcinoma with Flow CytometryJournal of Urology, VOL. 133, NO. 5, (786-788), Online publication date: 1-May-1985.Catalona W (2018) Editorial CommentJournal of Urology, VOL. 133, NO. 5, (788-788), Online publication date: 1-May-1985.Morales A (2018) Long-Term Results and Complications of Intracavitary Bacillus Calmette-Guerin Therapy for Bladder CancerJournal of Urology, VOL. 132, NO. 3, (457-459), Online publication date: 1-Sep-1984.Reichert D and Lamm D (2018) Long Term Protection in Bladder Cancer Following Intralesional ImmunotherapyJournal of Urology, VOL. 132, NO. 3, (570-573), Online publication date: 1-Sep-1984.Netto N and Lemos G (2018) Bacillus Calmette-Guerin Immunotherapy of Infiltrating Bladder CancerJournal of Urology, VOL. 132, NO. 4, (675-676), Online publication date: 1-Oct-1984.Lamm D (2018) Editorial CommentsJournal of Urology, VOL. 132, NO. 4, (676-676), Online publication date: 1-Oct-1984.Droller M (2018) Editorial CommentsJournal of Urology, VOL. 132, NO. 4, (676-677), Online publication date: 1-Oct-1984.Shapiro A, Ratliff T, Oakley D and Catalona W (2018) Comparison of the Efficacy of Intravesical Bacillus Calmette-Guérin with Thiotepa, Mitomycin C, Poly I:C/Poly-L-Lysine and Cis Platinum in Murine Bladder CancerJournal of Urology, VOL. 131, NO. 1, (139-142), Online publication date: 1-Jan-1984.Crispen R (2018) Re: Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, VOL. 131, NO. 3, (558-558), Online publication date: 1-Mar-1984.Netto N and Lemos G (2018) A Comparison of Treatment Methods for the Prophylaxis of Recurrent Superficial Bladder TumorsJournal of Urology, VOL. 129, NO. 1, (33-34), Online publication date: 1-Jan-1983.Morales A (2018) Editorial CommentJournal of Urology, VOL. 129, NO. 1, (34-34), Online publication date: 1-Jan-1983. (2018) Reply by AuthorJournal of Urology, VOL. 129, NO. 1, (34-34), Online publication date: 1-Jan-1983.Elhilali M, Ibrahim E, Nigam V, Brailovsky C and Madarnas P (2018) A Comparative Study of the Intravesical MTP and BCG Treatment of Transplantable Bladder CancerJournal of Urology, VOL. 129, NO. 6, (1265-1269), Online publication date: 1-Jun-1983.Mcroherts J (2018) Editorial CommentJournal of Urology, VOL. 129, NO. 1, (34-34), Online publication date: 1-Jan-1983.Brosman S (2018) Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, VOL. 128, NO. 1, (27-30), Online publication date: 1-Jul-1982.Shapiro A, Kadmon D, Catalona W and Ratliff T (2018) Immunotherapy of Superficial Bladder CancerJournal of Urology, VOL. 128, NO. 5, (891-894), Online publication date: 1-Nov-1982.Lamm D, Thor D, Stogdill V and Radwin H (2018) Bladder Cancer ImmunotherapyJournal of Urology, VOL. 128, NO. 5, (931-935), Online publication date: 1-Nov-1982.Lamm D, Reichert D, Harris S and Lucio R (2018) Immunotherapy of Murine Transitional Cell CarcinomaJournal of Urology, VOL. 128, NO. 5, (1104-1108), Online publication date: 1-Nov-1982. (2018) Reply by AuthorsJournal of Urology, VOL. 127, NO. 2, (235-235), Online publication date: 1-Feb-1982.Pang A and Morales A (2018) Immunoprophylaxis of a Murine Bladder Cancer with High Dose Bcg ImmunizationsJournal of Urology, VOL. 127, NO. 5, (1006-1009), Online publication date: 1-May-1982.Pang A and Morales A (2018) BCG Induced Murine Peritoneal Exudate Cells: Cytotoxic Activity Against a Syngeneic Bladder Tumor Cell LineJournal of Urology, VOL. 127, NO. 6, (1225-1229), Online publication date: 1-Jun-1982.Morales A, Ottenhof P and Emerson L (2018) Treatment of Residual, Non-infiltrating Bladder Cancer with Bacillus Calmette-guerinJournal of Urology, VOL. 125, NO. 5, (649-651), Online publication date: 1-May-1981.Lamm D, Thor D, Harris S, Reyna J, Stogdill V and Radwin H (2018) Bacillus Calmette-guerin Immunotherapy of Superficial Bladder CancerJournal of Urology, VOL. 124, NO. 1, (38-42), Online publication date: 1-Jul-1980.Soloway M (2018) Bladder Cancer—Part IIIJournal of Urology, VOL. 124, NO. 1, (47-47), Online publication date: 1-Jul-1980.Soloway M (2018) Rationale for Intensive Intravesical Chemotherapy for Superficial Bladder CancerJournal of Urology, VOL. 123, NO. 4, (461-466), Online publication date: 1-Apr-1980.Kagawa S, ogura K, Kurokawa K and Uyama K (2018) Immunological Evaluation of A Streptococcal Preparation (Ok-432) in Treatment of Bladder CarcinomaJournal of Urology, VOL. 122, NO. 4, (467-470), Online publication date: 1-Oct-1979.Droller M (2018) Bladder Cancer: Pebbles to Reach the WaterJournal of Urology, VOL. 122, NO. 4, (476-477), Online publication date: 1-Oct-1979.Grossman H (2018) Current Therapy of Bladder CarcinomaJournal of Urology, VOL. 121, NO. 1, (1-7), Online publication date: 1-Jan-1979.Banks M, Pontes J, Izbicki R and Pierce J (2018) Topical Instillation of Doxorubicin Hydrochloride in the Treatment of Recurring Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 118, NO. 5, (757-760), Online publication date: 1-Nov-1977. Volume 116Issue 2August 1976Page: 180-182 Advertisement Copyright & Permissions© 1976 by The American Urological Association Education and Research, Inc.MetricsAuthor Information A. Morales Current address: Laboratory of Immunodiagnosis, Building 8, Room 118, National Institutes of Health, Bethesda, Maryland, 20014. More articles by this author D. Eidinger More articles by this author A.W. Bruce More articles by this author Expand All Advertisement PDF downloadLoading ...